BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jiangsu Vcare Pharmaceutical Technology Co.\, Ltd. readouts ·
  AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jiangsu Vcare Pharmaceutical Tech
 nology Co.\, Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06577519-8692@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sumecigrel: Phase 3 readout est. (NCT06577519)
DESCRIPTION:Sumecigrel\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Efficacy and Safety Study of Vicagrel in Patients With Acute Coron
 ary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sumecigrel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06577519
URL:https://assetmemo.bio/drug/sumecigrel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
